Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chugai To Remain Unscathed By Roche's Internal Restructuring And Cost-cutting Measures

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche CEO Schwan also informed analysts that the company is not considering expanding its business into other areas such as a pharmaceutical generics or biosimilars.

You may also be interested in...

Roche Launches Avastin In China For Colon And Rectal Cancer Following Counterfeit Drug Incident In Shanghai

SHANGHAI - Roche announced Sept. 26 the formal launch of its anti-VEGF monoclonal antibody Avastin (bevacizumab) in China for the treatment of metastatic colon and rectal cancer. Roche will also be pursuing other cancer indications in China for the drug

Roche/Ipsen's Suspended Taspoglutide Could Become Another Diabetes Casualty

Roche confirms suspension of dosing in Phase III taspoglutide program after reporting safety problems in June. But Roche's pain could be a gain for the competing GLP-1 Bydureon from Lilly/Amylin/Alkermes.

Roche Announces Internal Review Likely To Result In Staff, Program Cuts

Swiss pharma cites U.S. and EU health care spending constraints and regulatory setbacks as reasons for plan.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts